Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KEVIN D CANNON

Allopathic & Osteopathic Physicians Hospitalist

NPI
1700897022
CMS profile
122867
Location
WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,301.48

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,373.69 8
Food and Beverage $927.79 8

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk AS $2,070.51 10
PFIZER INC. $1,199.47 5
Philips Electronics North America Corporation $31.50 1

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KEVIN D CANNON

NPI 1700897022 · CMS profile ID 122867

Allopathic & Osteopathic Physicians / Hospitalist

WILMINGTON, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700897022?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700897022?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700897022?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
KEVIN D CANNON, NPI 1700897022, CMS profile ID 122867, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1700897022?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $3,301.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk AS $726.1508/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542177 CMS
Novo Nordisk AS $192.6608/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542179 CMS
Novo Nordisk AS $193.3608/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544055 CMS
Philips Electronics North America Corporation $31.5006/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684078585 CMS
Novo Nordisk AS $50.0002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544045 CMS
Novo Nordisk AS $25.0002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544047 CMS
Novo Nordisk AS $50.0002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544049 CMS
Novo Nordisk AS $25.0002/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544051 CMS
Novo Nordisk AS $223.8802/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542173 CMS
Novo Nordisk AS $459.4602/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703542175 CMS
Novo Nordisk AS $125.0002/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544053 CMS
PFIZER INC. $30.0002/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672596577 CMS
PFIZER INC. $270.0701/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672186377 CMS
PFIZER INC. $427.9301/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672197431 CMS
PFIZER INC. $370.2001/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672213845 CMS
PFIZER INC. $101.2701/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672223843 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,301.48 16
PY2021 $20.00 1
PY2022 $58.19 2
PY2023 $1,400.30 14
PY2025 $116.03 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $3,200.00 1
PY2025 Principal investigator $6,407,903.58 738
PY2024 Recipient $12,299.41 13
PY2024 Principal investigator $7,058,469.69 390
PY2023 Recipient $3,980.00 2
PY2023 Principal investigator $7,125,617.33 899
PY2022 Recipient $9,082.00 12
PY2022 Principal investigator $6,929,547.49 979
PY2021 Recipient $14,312.20 61
PY2021 Principal investigator $9,361,495.59 2,459
PY2020 Recipient $233.41 1
PY2020 Principal investigator $5,812,787.31 750
PY2019 Principal investigator $4,820,055.08 826

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

991 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novo Nordisk AS $23.06 12/28/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897164475
Principal investigator 1 Novo Nordisk AS $23.06 12/28/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897226861
Principal investigator 1 PFIZER INC. $4,138.00 12/28/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949776087
Principal investigator 1 Janssen Pharmaceuticals, Inc $16,978.00 12/27/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219385
Principal investigator 1 GlaxoSmithKline, LLC. $7,500.00 12/23/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 943933759
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 12/23/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 943933765
Principal investigator 1 Novo Nordisk AS $23.06 12/22/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897164751
Principal investigator 1 Novo Nordisk AS $10.00 12/22/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267853
Principal investigator 1 Novo Nordisk AS $23.06 12/22/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897271665
Principal investigator 1 Novo Nordisk AS $10.00 12/22/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897294069
Principal investigator 1 Bavarian Nordic A/S $19,817.00 12/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246807
Principal investigator 1 GlaxoSmithKline, LLC. $27,490.32 12/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 943933763
Principal investigator 1 Novo Nordisk AS $748.71 12/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896957967
Principal investigator 1 Novo Nordisk AS $847.87 12/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001181
Principal investigator 1 Novo Nordisk AS $1,866.94 12/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897184251
Principal investigator 1 Novo Nordisk AS $2,464.39 12/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897226007
Principal investigator 1 Novo Nordisk AS $735.66 12/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897271984
Principal investigator 1 PFIZER INC. $84,978.36 12/21/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949771717
Principal investigator 1 PFIZER INC. $2,572.86 12/21/2022 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949771801
Principal investigator 1 PFIZER INC. $78,665.40 12/17/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949771625
Principal investigator 1 Janssen Pharmaceuticals, Inc $21,966.00 12/16/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219369
Principal investigator 1 Novo Nordisk AS $23.06 12/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897226801
Principal investigator 1 Novo Nordisk AS $23.06 12/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897269629
Principal investigator 1 PFIZER INC. $10,820.00 12/16/2022 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 949771627
Principal investigator 1 PFIZER INC. $105,668.10 12/16/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949771629
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896852153
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896852155
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896852157
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896852159
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896852177
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896869935
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896889853
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896889857
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896913559
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896913615
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896913641
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896913643
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896919027
Principal investigator 1 Novo Nordisk AS $31.96 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896924651
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896925359
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896925363
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896957971
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896957975
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897000127
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897025229
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897025233
Principal investigator 1 Novo Nordisk AS $31.96 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897073917
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897075352
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897121129
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897121201
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897121721
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897123561
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897127961
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897127965
Principal investigator 1 Novo Nordisk AS $21.64 12/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897127969
Principal investigator 1 Bavarian Nordic A/S $33,587.00 12/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246767
Principal investigator 1 Novo Nordisk AS $30.78 12/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897110379
Principal investigator 1 Novo Nordisk AS $30.78 12/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897137611
Principal investigator 1 Novo Nordisk AS $8.55 12/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897137617
Principal investigator 1 Novo Nordisk AS $43.92 12/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897137621
Principal investigator 1 Novo Nordisk AS $43.92 12/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897145163
Principal investigator 1 Novo Nordisk AS $30.78 12/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897145167
Principal investigator 1 Novo Nordisk AS $30.78 12/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897145171
Principal investigator 1 Novo Nordisk AS $30.78 12/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897194947
Principal investigator 1 Novo Nordisk AS $43.92 12/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897194967
Principal investigator 1 Novo Nordisk AS $30.78 12/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897195023
Principal investigator 1 Novo Nordisk AS $43.92 12/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897195035
Principal investigator 1 PFIZER INC. $9,433.82 12/14/2022 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949771797
Principal investigator 1 PFIZER INC. $413.83 12/14/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949773607
Principal investigator 1 PFIZER INC. $342,847.98 12/10/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949771799
Principal investigator 1 PFIZER INC. $4,207.95 12/09/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949771715
Principal investigator 1 Novo Nordisk AS $23.06 12/07/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897119497
Principal investigator 1 PFIZER INC. $1,715.24 12/07/2022 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949770687
Principal investigator 1 PFIZER INC. $13,005.41 12/07/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949776265
Principal investigator 1 Bavarian Nordic A/S $24,508.00 12/06/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246717
Principal investigator 1 Novo Nordisk AS $23.06 12/06/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897164471
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897164743
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897164747
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897164755
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897164759
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897215901
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897217129
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897217335
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897217341
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897240877
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897240881
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897240885
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897241031
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897241033
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897241039
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267745
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267773
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267777
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267781
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267857
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267861
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267865
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267869
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897272011
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897272015
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897272023
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897272027
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897272151
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897287241
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897287245
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897287249
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897287257
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897294053
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897294057
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897294061
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897294065
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897294074
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897294077
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897294081
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897304247
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897304251
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897304253
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897304259
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897304263
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897304265
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897304269
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897304273
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897304277
Principal investigator 1 Novo Nordisk AS $28.45 12/06/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897304281
Principal investigator 1 PFIZER INC. $37.26 12/06/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759933
Principal investigator 1 Janssen Pharmaceuticals, Inc $21,809.00 12/05/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219374
Principal investigator 1 PFIZER INC. $161,136.66 12/03/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949770685
Principal investigator 1 Novo Nordisk AS $3,964.39 12/02/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897219560
Principal investigator 1 Bavarian Nordic A/S $73,575.00 12/01/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246699
Principal investigator 1 Novo Nordisk AS $351.00 11/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 896963861
Principal investigator 1 Novo Nordisk AS $1,459.44 11/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897000123
Principal investigator 1 Novo Nordisk AS $527.25 11/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009381
Principal investigator 1 PFIZER INC. $3,888.00 11/30/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949780573
Principal investigator 1 PFIZER INC. $12,006.68 11/30/2022 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949780921
Principal investigator 1 PFIZER INC. $7,093.86 11/24/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949781261
Principal investigator 1 Novo Nordisk AS $4,724.70 11/23/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897226853
Principal investigator 1 PFIZER INC. $168,986.76 11/23/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949780925
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963554865
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963554867
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963554869
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963554871
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963554873
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963554875
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963554877
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963554879
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963554881
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555113
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555115
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555117
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555119
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555121
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555123
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555125
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555127
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555129
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555131
Principal investigator 1 ModernaTX, Inc. $815.67 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555133
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555135
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555137
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555139
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555141
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555143
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555145
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555147
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555149
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555151
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555153
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555155
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555157
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555159
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555161
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555163
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555165
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555167
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555169
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555171
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555173
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555175
Principal investigator 1 ModernaTX, Inc. $815.67 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555177
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555179
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555181
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555183
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555185
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555187
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555189
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555191
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555193
Principal investigator 1 ModernaTX, Inc. $815.67 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555195
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555197
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555199
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555201
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555203
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555205
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555207
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555209
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555211
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555213
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555215
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555217
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555219
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555221
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555223
Principal investigator 1 ModernaTX, Inc. $537.37 11/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963555225
Principal investigator 1 Novo Nordisk AS $10.26 11/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897110375
Principal investigator 1 Novo Nordisk AS $10.26 11/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897194955
Principal investigator 1 Novo Nordisk AS $10.26 11/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897195027
Principal investigator 1 Novo Nordisk AS $10.26 11/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897206307
Principal investigator 1 Novo Nordisk AS $2.85 11/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897206319
Principal investigator 1 PFIZER INC. $167.67 11/21/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759661
Principal investigator 1 Novo Nordisk AS $23.06 11/18/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897251435
Principal investigator 1 PFIZER INC. $93.15 11/17/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759489
Principal investigator 1 PFIZER INC. $3,001.40 11/17/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 1 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949780923
Principal investigator 1 PFIZER INC. $37.26 11/16/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759485
Principal investigator 1 PFIZER INC. $857.62 11/16/2022 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949780879
Principal investigator 1 PFIZER INC. $6,251.85 11/16/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949781315
Principal investigator 1 Bavarian Nordic A/S $49,779.00 11/15/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246779
Principal investigator 1 Novo Nordisk AS $10.00 11/15/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897217325
Principal investigator 1 Novo Nordisk AS $23.06 11/15/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897287253
Principal investigator 1 Novo Nordisk AS $23.06 11/11/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897269625
Principal investigator 1 Novo Nordisk AS $82.08 11/10/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897033177
Principal investigator 1 Novo Nordisk AS $22.80 11/10/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897194959
Principal investigator 1 Novo Nordisk AS $82.08 11/10/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897195031
Principal investigator 1 Novo Nordisk AS $82.08 11/10/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897206311
Principal investigator 1 Novo Nordisk AS $82.08 11/10/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897206315
Principal investigator 1 PFIZER INC. $143,291.04 11/10/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949780881
Principal investigator 1 PFIZER INC. $37.26 11/09/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759301
Principal investigator 1 PFIZER INC. $6,003.34 11/09/2022 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949780877
Principal investigator 1 PFIZER INC. $83,876.88 11/09/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949781263
Principal investigator 1 Bavarian Nordic A/S $12,544.00 11/08/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246739
Principal investigator 1 PFIZER INC. $37.26 11/08/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759663
Principal investigator 1 PFIZER INC. $86,474.40 11/08/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949781259
Principal investigator 1 PFIZER INC. $28,268.58 11/05/2022 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949780575
Principal investigator 1 PFIZER INC. $32,031.34 11/05/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949780751
Principal investigator 1 Bavarian Nordic A/S $19,997.00 11/02/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246711
Principal investigator 1 PFIZER INC. $55.89 11/02/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759487
Principal investigator 1 PFIZER INC. $270,043.39 11/02/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949780749
Principal investigator 1 PFIZER INC. $38,129.84 10/29/2022 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949787429
Principal investigator 1 Novo Nordisk AS $10.00 10/28/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897164739
Principal investigator 1 Novo Nordisk AS $23.06 10/28/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897294049
Principal investigator 1 PFIZER INC. $58,370.22 10/28/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949787405
Principal investigator 1 PFIZER INC. $12,270.30 10/27/2022 Non-covered Recipient Entity
ACCELLACARE WILMINGTON
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 949778575
Principal investigator 1 PFIZER INC. $1,512.81 10/27/2022 Non-covered Recipient Entity
ACCELLACARE WILMINGTON
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 949778599
Principal investigator 1 PFIZER INC. $821.96 10/27/2022 Non-covered Recipient Entity
ACCELLACARE WILMINGTON
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 949778601
Principal investigator 1 PFIZER INC. $825.62 10/27/2022 Non-covered Recipient Entity
ACCELLACARE WILMINGTON
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 949778637
Principal investigator 1 PFIZER INC. $226.00 10/27/2022 Non-covered Recipient Entity
ACCELLACARE WILMINGTON
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 2 RANDOMIZED DOUBLEBLIND 2ARM STUDY TO INVESTIGATE A REPEAT 5DAY COURSE OF NIRMATRELVIRRITONAVIR COMPARED TO PLACEBORITONAVIR IN PARTICIPANTS AT LEAST 12 YEARS OF AGE WITH REBOUND OF COVID19 SYMPTOMS AND RAPID ANTIGEN TEST POSITIVITY No dispute reported 06/30/2026 949778639
Principal investigator 1 PFIZER INC. $1,957.50 10/27/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949793063
Principal investigator 1 PFIZER INC. $26,470.47 10/27/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949793425
Principal investigator 1 Bavarian Nordic A/S $50,568.00 10/26/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246837
Principal investigator 1 Janssen Pharmaceuticals, Inc $19,548.00 10/26/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219381
Principal investigator 1 PFIZER INC. $1,799.55 10/26/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949787427
Principal investigator 1 Novo Nordisk AS $23.06 10/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897119493
Principal investigator 1 PFIZER INC. $37.26 10/25/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759665
Principal investigator 1 PFIZER INC. $74.52 10/25/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759849
Principal investigator 1 PFIZER INC. $11,832.80 10/25/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 1 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949787909
Principal investigator 1 Novo Nordisk AS $1,902.37 10/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918639
Principal investigator 1 Novo Nordisk AS $3,247.82 10/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897073913
Principal investigator 1 Novo Nordisk AS $2,329.88 10/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897107909
Principal investigator 1 Novo Nordisk AS $4,202.15 10/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897119489
Principal investigator 1 Novo Nordisk AS $4,918.78 10/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897172389
Principal investigator 1 PFIZER INC. $37.26 10/20/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759847
Principal investigator 1 PFIZER INC. $166,170.04 10/19/2022 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949787403
Principal investigator 1 Bavarian Nordic A/S $27,199.00 10/18/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246797
Principal investigator 1 PFIZER INC. $19,456.74 10/18/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949787401
Principal investigator 1 Novo Nordisk AS $23.06 10/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897251431
Principal investigator 1 Novo Nordisk AS $23.06 10/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897185489
Principal investigator 1 PFIZER INC. $4,698.00 10/14/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949793423
Principal investigator 1 PFIZER INC. $32,427.90 10/13/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949787425
Principal investigator 1 Bavarian Nordic A/S $24,902.00 10/12/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246761
Principal investigator 1 PFIZER INC. $337.61 10/10/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949759935
Principal investigator 1 PFIZER INC. $4,729.24 10/08/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949792911
Principal investigator 1 Bavarian Nordic A/S $16,830.00 10/07/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246723
Principal investigator 1 PFIZER INC. $14,644.18 10/07/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 1 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949787893
Principal investigator 1 ModernaTX, Inc. $167.50 10/06/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PULMONARY
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963325921
Principal investigator 1 ModernaTX, Inc. $21.00 10/06/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PULMONARY
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963325927
Principal investigator 1 PFIZER INC. $74.52 10/05/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759851
Principal investigator 1 Novo Nordisk AS $29.28 10/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897073609
Principal investigator 1 Novo Nordisk AS $82.08 10/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897110369
Principal investigator 1 Novo Nordisk AS $82.08 10/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897137613
Principal investigator 1 Novo Nordisk AS $29.28 10/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897137625
Principal investigator 1 Novo Nordisk AS $22.80 10/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897137763
Principal investigator 1 Novo Nordisk AS $82.08 10/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897145159
Principal investigator 1 Novo Nordisk AS $29.28 10/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897194889
Principal investigator 1 Novo Nordisk AS $29.28 10/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897194963
Principal investigator 1 Novo Nordisk AS $82.08 10/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9932-4954 No dispute reported 06/30/2026 897206303
Principal investigator 1 Novo Nordisk AS $23.06 10/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897226111
Principal investigator 1 PFIZER INC. $22,096.80 10/01/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949787455
Principal investigator 1 Novo Nordisk AS $525.94 09/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896928165
Principal investigator 1 Novo Nordisk AS $3,452.52 09/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897136425
Principal investigator 1 Novo Nordisk AS $900.00 09/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897164459
Principal investigator 1 Novo Nordisk AS $3,405.43 09/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897225241
Principal investigator 1 PFIZER INC. $22,099.50 09/30/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949796557
Principal investigator 1 Bavarian Nordic A/S $22,269.00 09/28/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246847
Principal investigator 1 Novo Nordisk AS $847.87 09/28/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896924961
Principal investigator 1 Novo Nordisk AS $23.06 09/28/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896949899
Principal investigator 1 Novo Nordisk AS $437.60 09/28/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897075463
Principal investigator 1 Novo Nordisk AS $4,563.57 09/28/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897186687
Principal investigator 1 PFIZER INC. $54,559.28 09/28/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949796491
Principal investigator 1 PFIZER INC. $314.55 09/28/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949796555
Principal investigator 1 PFIZER INC. $93.15 09/27/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949760109
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,588.00 09/26/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219285
Principal investigator 1 ModernaTX, Inc. $6,360.00 09/26/2022 Non-covered Recipient Entity
PMG RESEARCH OF WILMINGTON
A PHASE 3, RANDOMIZED, OBSERVER-BLIND, ACTIVE-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1010 CANDIDATE SEASONAL INFLUENZA VACCINE IN ADULTS 50 YEARS AND OLDER No dispute reported 06/30/2026 963224459
Principal investigator 1 Novo Nordisk AS $23.06 09/26/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896965895
Principal investigator 1 PFIZER INC. $31,711.50 09/24/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949796559
Principal investigator 1 Janssen Pharmaceuticals, Inc $21,610.00 09/23/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219289
Principal investigator 1 PFIZER INC. $91,782.53 09/22/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 1 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949793493
Principal investigator 1 PFIZER INC. $119,693.39 09/22/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949797065
Principal investigator 1 Bavarian Nordic A/S $43,734.00 09/20/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246801
Principal investigator 1 GlaxoSmithKline, LLC. $15,300.00 09/16/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CEN No dispute reported 06/30/2026 943933767
Principal investigator 1 ModernaTX, Inc. $332.00 09/16/2022 Non-covered Recipient Entity
WILMINGTON HEALTH PULMONARY
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 963325863
Principal investigator 1 Novo Nordisk AS $28.20 09/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896860819
Principal investigator 1 Novo Nordisk AS $23.06 09/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896902907
Principal investigator 1 Novo Nordisk AS $28.20 09/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918875
Principal investigator 1 Novo Nordisk AS $28.20 09/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918880
Principal investigator 1 Novo Nordisk AS $23.06 09/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896949903
Principal investigator 1 Novo Nordisk AS $28.20 09/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896983823
Principal investigator 1 Novo Nordisk AS $28.20 09/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896985081
Principal investigator 1 Novo Nordisk AS $28.20 09/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001217
Principal investigator 1 Novo Nordisk AS $28.20 09/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001269
Principal investigator 1 Novo Nordisk AS $28.20 09/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001445
Principal investigator 1 Novo Nordisk AS $28.20 09/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897107085
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896957749
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896957753
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896957757
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896957813
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897000067
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897000173
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897024519
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897025221
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897025225
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897073893
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897073897
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897075399
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897075407
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897121109
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897121113
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897121117
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897121121
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897121125
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897122339
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897122343
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897122351
Principal investigator 1 Novo Nordisk AS $30.00 09/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897127957
Principal investigator 1 Bavarian Nordic A/S $2,897.00 09/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246773
Principal investigator 1 PFIZER INC. $37.26 09/12/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759577
Principal investigator 1 PFIZER INC. $93.15 09/10/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949759579
Principal investigator 1 Bavarian Nordic A/S $60,595.00 09/07/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246729
Principal investigator 1 Novo Nordisk AS $23.06 09/07/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896959015
Principal investigator 1 Novo Nordisk AS $23.06 09/07/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897073909
Principal investigator 1 PFIZER INC. $11,320.00 09/07/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 949797067
Principal investigator 1 Novo Nordisk AS $23.06 09/06/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896949907
Principal investigator 1 GlaxoSmithKline, LLC. $70,187.76 09/01/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CEN No dispute reported 06/30/2026 943933757
Principal investigator 1 GlaxoSmithKline, LLC. $14,999.04 09/01/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CEN No dispute reported 06/30/2026 943933761
Principal investigator 1 GlaxoSmithKline, LLC. $17,714.59 09/01/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE I/II OBSERVER-BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTI-CEN No dispute reported 06/30/2026 943933769
Recipient PFIZER INC. $3,200.00 08/31/2022 Covered Recipient Physician PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 949750479
Principal investigator 1 PFIZER INC. $84,260.80 08/31/2022 Non-covered Recipient Entity
Accellacare US Inc
AN INTERVENTIONAL RANDOMIZED ACTIVECONTROLLED PHASE 23 STUDY TO INVESTIGATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF BIVALENT BNT162B RNABASED VACCINE CANDIDATES AS A BOOSTER DOSE IN COVID19 VACCINEEXPERIENCED HEALTHY INDIVIDUALS No dispute reported 06/30/2026 949787635
Principal investigator 1 Novo Nordisk AS $23.06 08/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896869939
Principal investigator 1 Janssen Pharmaceuticals, Inc $40,916.00 08/26/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219281
Principal investigator 1 Novo Nordisk AS $6,733.17 08/26/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897210689
Principal investigator 1 Novo Nordisk AS $300.00 08/26/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897226003
Principal investigator 1 Novo Nordisk AS $23.06 08/24/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896889849
Principal investigator 1 PFIZER INC. $444.18 08/24/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 1 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949699905
Principal investigator 1 PFIZER INC. $465.52 08/24/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 1 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949701533
Principal investigator 1 PFIZER INC. $500.00 08/24/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949803121
Principal investigator 1 Bavarian Nordic A/S $6,399.00 08/23/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246831
Principal investigator 1 PFIZER INC. $96.46 08/23/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949760285
Principal investigator 1 PFIZER INC. $7,789.50 08/23/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949800915
Principal investigator 1 Bavarian Nordic A/S $17,322.00 08/22/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246819
Principal investigator 1 Novo Nordisk AS $868.66 08/22/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976239
Principal investigator 1 Novo Nordisk AS $637.03 08/22/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897057703
Principal investigator 1 Novo Nordisk AS $748.71 08/22/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897073905
Principal investigator 1 Novo Nordisk AS $3,250.71 08/22/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897119485
Principal investigator 1 PFIZER INC. $578.76 08/22/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949760107
Principal investigator 1 Novo Nordisk AS $23.06 08/19/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897185493
Principal investigator 1 Novo Nordisk AS $23.06 08/19/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897225257
Principal investigator 1 Bavarian Nordic A/S $17,129.00 08/17/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246791
Principal investigator 1 PFIZER INC. $11,475.00 08/17/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949801087
Principal investigator 1 PFIZER INC. $4,357.41 08/17/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949804375
Principal investigator 1 PFIZER INC. $351.00 08/16/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949803891
Principal investigator 1 Novo Nordisk AS $23.06 08/12/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897225871
Principal investigator 1 Novo Nordisk AS $23.06 08/12/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897226865
Principal investigator 1 Bavarian Nordic A/S $16,814.00 08/11/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246751
Principal investigator 1 PFIZER INC. $1,396.56 08/10/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 1 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949701547
Principal investigator 1 PFIZER INC. $1,332.54 08/10/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 1 RANDOMIZED OPENLABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF PNEUMOCOCCAL CONJUGATE FORMULATIONS IN HEALTHY ADULTS 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949701561
Principal investigator 1 Bavarian Nordic A/S $50,568.00 08/09/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246745
Principal investigator 1 Novo Nordisk AS $139.34 08/08/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897226239
Principal investigator 1 Novo Nordisk AS $139.34 08/08/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897269633
Principal investigator 1 PFIZER INC. $482.30 08/08/2022 Non-covered Recipient Entity
Accellacare Wilmington
A PHASE 2B PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A HEXAVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS DIPHTHERIA AND ACELLULAR PERTUSSIS VACCINE TDAP IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE No dispute reported 06/30/2026 949759753
Principal investigator 1 PFIZER INC. $23,201.10 08/04/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949802513
Principal investigator 1 PFIZER INC. $413.83 08/03/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949803691
Principal investigator 1 Bavarian Nordic A/S $87,414.00 08/02/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246705
Principal investigator 1 PFIZER INC. $8,424.00 07/29/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949807091
Principal investigator 1 PFIZER INC. $1,241.49 07/28/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949807089
Principal investigator 1 Bavarian Nordic A/S $18,651.00 07/27/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246842
Principal investigator 1 Novo Nordisk AS $2,052.27 07/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896902915
Principal investigator 1 Novo Nordisk AS $2,968.75 07/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009373
Principal investigator 1 Novo Nordisk AS $3,607.33 07/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 897016367
Principal investigator 1 Novo Nordisk AS $1,123.07 07/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897121105
Principal investigator 1 Novo Nordisk AS $3,401.45 07/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897143659
Principal investigator 1 Novo Nordisk AS $3,990.65 07/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897210433
Principal investigator 1 Novo Nordisk AS $23.06 07/26/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897164467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,349.67 07/25/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938667523
Principal investigator 1 Janssen Pharmaceuticals, Inc $69,527.00 07/22/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219279
Principal investigator 1 Bavarian Nordic A/S $53,768.00 07/21/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246813
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 896921953
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 896921957
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 896921961
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 896967759
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 896967763
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 896967767
Principal investigator 1 Novo Nordisk AS $5.70 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 896967771
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897011219
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897011408
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897011421
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897012229
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897043507
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897043511
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897044905
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897044909
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897047027
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897048685
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897048689
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897048693
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897075653
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897075715
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897079679
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897079683
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897079687
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897079691
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897079695
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897079699
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897086393
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897086397
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897086401
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897086405
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897086409
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897086413
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897086417
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897087229
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897087233
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897087237
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897087241
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897087245
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897087249
Principal investigator 1 Novo Nordisk AS $9.00 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897087253
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897087257
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897118323
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897118841
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897118845
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897118853
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897118861
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897119031
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897119121
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897119145
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897119149
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897119152
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897119157
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897119159
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897119165
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897119169
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897119173
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897119305
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897164675
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897164731
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897164735
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897164763
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897175789
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897175793
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897175797
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897175801
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897175805
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897175809
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897176581
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897176582
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897176587
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897176695
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897176701
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897176703
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897176707
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897176713
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897176723
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897176727
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897176731
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897177557
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897177561
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897177565
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897177569
Principal investigator 1 Novo Nordisk AS $2.95 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897177573
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897177577
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897217319
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897217345
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897217348
Principal investigator 1 Novo Nordisk AS $6.50 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897240541
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897241043
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897241045
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267761
Principal investigator 1 Novo Nordisk AS $9.00 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267765
Principal investigator 1 Novo Nordisk AS $36.00 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897267769
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897272003
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897272007
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897272031
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897286543
Principal investigator 1 Novo Nordisk AS $60.00 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897287115
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897287261
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897293874
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897293983
Principal investigator 1 Novo Nordisk AS $9.98 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897294037
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897294085
Principal investigator 1 Novo Nordisk AS $11.38 07/21/2022 Non-covered Recipient Entity
PMG RES OF WILMINGTON, LLC
NN9535-4984 No dispute reported 06/30/2026 897304285
Principal investigator 1 PFIZER INC. $243.00 07/21/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949807167
Principal investigator 1 Novo Nordisk AS $23.06 07/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897164463
Principal investigator 1 PFIZER INC. $27,560.25 07/20/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949806869
Principal investigator 1 Novo Nordisk AS $23.06 07/19/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897251427
Principal investigator 1 Novo Nordisk AS $139.34 07/18/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896857727
Principal investigator 1 Novo Nordisk AS $0.23 07/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854043
Principal investigator 1 Novo Nordisk AS $0.23 07/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854067
Principal investigator 1 Novo Nordisk AS $18.00 07/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896888731
Principal investigator 1 Novo Nordisk AS $23.06 07/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896905723
Principal investigator 1 Novo Nordisk AS $0.23 07/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896927481
Principal investigator 1 Novo Nordisk AS $0.23 07/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896928827
Principal investigator 1 PFIZER INC. $28,614.60 07/13/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949805935
Principal investigator 1 Bavarian Nordic A/S $49,783.00 07/12/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246757
Principal investigator 1 Bavarian Nordic A/S $72,758.00 07/08/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246733
Principal investigator 1 PFIZER INC. $750.00 07/08/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949792979
Principal investigator 1 Novo Nordisk AS $23.06 07/07/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896949919
Principal investigator 1 Novo Nordisk AS $23.06 07/07/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897073901
Principal investigator 1 PFIZER INC. $292.95 07/06/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949807093
Principal investigator 1 Novo Nordisk AS $3.16 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854065
Principal investigator 1 Novo Nordisk AS $11.43 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921789
Principal investigator 1 Novo Nordisk AS $3.16 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921793
Principal investigator 1 Novo Nordisk AS $8.25 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921805
Principal investigator 1 Novo Nordisk AS $3.16 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896924993
Principal investigator 1 Novo Nordisk AS $3.16 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896927497
Principal investigator 1 Novo Nordisk AS $3.16 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896928819
Principal investigator 1 Novo Nordisk AS $3.16 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896928823
Principal investigator 1 Novo Nordisk AS $8.25 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896930827
Principal investigator 1 Novo Nordisk AS $3.16 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896930843
Principal investigator 1 Novo Nordisk AS $3.16 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896930847
Principal investigator 1 Novo Nordisk AS $3.16 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896975963
Principal investigator 1 Novo Nordisk AS $3.16 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897031149
Principal investigator 1 Novo Nordisk AS $3.16 07/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897105451
Principal investigator 1 Bavarian Nordic A/S $79,040.00 06/30/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246853
Principal investigator 1 Novo Nordisk AS $70.00 06/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897032419
Principal investigator 1 Novo Nordisk AS $3,619.68 06/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897074115
Principal investigator 1 PFIZER INC. $65.00 06/30/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949721837
Principal investigator 1 PFIZER INC. $2,250.00 06/30/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949723231
Principal investigator 1 PFIZER INC. $375.00 06/30/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949723249
Principal investigator 1 PFIZER INC. $50.00 06/30/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949723265
Principal investigator 1 PFIZER INC. $7,035.11 06/30/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949812479
Principal investigator 1 PFIZER INC. $74,259.45 06/30/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949812483
Principal investigator 1 Novo Nordisk AS $23.06 06/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896857729
Principal investigator 1 Novo Nordisk AS $2,380.50 06/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896862603
Principal investigator 1 Novo Nordisk AS $2,574.81 06/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896949911
Principal investigator 1 Novo Nordisk AS $9,477.56 06/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897241391
Principal investigator 1 PFIZER INC. $8,775.00 06/29/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949812481
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896859445
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896859447
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896859449
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896916497
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896916501
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896916505
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896922595
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896922607
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896922611
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896968073
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896968077
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896968081
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896979565
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896979569
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896979575
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896979581
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896983567
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896996719
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896997509
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897004595
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897004599
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897004603
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897079905
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897079927
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897079939
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897079943
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897079947
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897079951
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897079959
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897079963
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897079985
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897122529
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897123067
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897123071
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897123076
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897123643
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897123647
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897123651
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897123655
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897151561
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897151566
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897151569
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897151573
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897151577
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897151581
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897151587
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897194219
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897194401
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195001
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195005
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195013
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195021
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195025
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195029
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195033
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195037
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195109
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195113
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195117
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195910
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195915
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195919
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195966
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897196135
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897226677
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897227181
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897227185
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897227189
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897227193
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897227197
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897227201
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897227205
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897227209
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897227213
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897227217
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897241395
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897241399
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897241403
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897241407
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897241411
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897242679
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897242683
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897242687
Principal investigator 1 Novo Nordisk AS $85.35 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897242691
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897242695
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897242699
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897242703
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897242707
Principal investigator 1 Novo Nordisk AS $65.00 06/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897242727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $739.67 06/23/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938649749
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,243.47 06/23/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938649757
Principal investigator 1 Bavarian Nordic A/S $7,904.00 06/22/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246825
Principal investigator 1 Novo Nordisk AS $23.06 06/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897176111
Principal investigator 1 Janssen Pharmaceuticals, Inc $94,281.00 06/20/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219203
Principal investigator 1 Novo Nordisk AS $23.06 06/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897117891
Principal investigator 1 Novo Nordisk AS $23.06 06/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897176115
Principal investigator 1 Bavarian Nordic A/S $21,736.00 06/16/2022 Non-covered Recipient Entity
ACCELLACARE US INC
NCT05238025 No dispute reported 06/30/2026 907246785
Principal investigator 1 Novo Nordisk AS $37.45 06/16/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897075395
Principal investigator 1 PFIZER INC. $2,281.50 06/15/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949810467
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $680,016.96 06/13/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938642389
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,873.16 06/13/2022 Non-covered Recipient Entity
PMG RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 No dispute reported 06/30/2026 938642533
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $101,167.00 06/13/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938642539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,759.46 06/13/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938642583
Principal investigator 1 Novo Nordisk AS $23.06 06/08/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897083697
Principal investigator 1 Novo Nordisk AS $23.06 06/07/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897176107
Principal investigator 1 Novo Nordisk AS $23.06 06/06/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897143653
Principal investigator 1 Novo Nordisk AS $2,288.32 06/03/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896985065
Principal investigator 1 PFIZER INC. $83.70 06/03/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MULTIPLE FORMULATIONS OF THE VACCINE CANDIDATE BNT162B2 AGAINST COVID 19 IN HEALTHY ADULTS 18 THROUGH 55 YEARS OF AGE No dispute reported 06/30/2026 949812127
Principal investigator 1 PFIZER INC. $6,420.60 06/03/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949812549
Principal investigator 1 Novo Nordisk AS $70.00 05/31/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 896960525
Principal investigator 1 Novo Nordisk AS $637.03 05/27/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897236115
Principal investigator 1 PFIZER INC. $1,930.50 05/27/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949750955
Principal investigator 1 Novo Nordisk AS $50.10 05/26/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896872237
Principal investigator 1 Novo Nordisk AS $50.10 05/26/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921749
Principal investigator 1 Novo Nordisk AS $50.10 05/26/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896927473
Principal investigator 1 Novo Nordisk AS $50.10 05/26/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897161989
Principal investigator 1 Novo Nordisk AS $300.00 05/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896965899
Principal investigator 1 Novo Nordisk AS $3,099.98 05/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896977893
Principal investigator 1 Novo Nordisk AS $710.72 05/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897122347
Principal investigator 1 Novo Nordisk AS $6,156.91 05/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195009
Principal investigator 1 PFIZER INC. $827.66 05/25/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949750944
Principal investigator 1 PFIZER INC. $63,547.20 05/21/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949750687
Principal investigator 1 PFIZER INC. $243.00 05/21/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949750691
Principal investigator 1 Janssen Pharmaceuticals, Inc $250,379.00 05/20/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219199
Principal investigator 1 Novo Nordisk AS $23.06 05/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897046759
Principal investigator 1 PFIZER INC. $1,930.50 05/14/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949750473
Principal investigator 1 Novo Nordisk AS $23.06 05/13/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896959363
Principal investigator 1 Novo Nordisk AS $23.06 05/13/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897176983
Principal investigator 1 Novo Nordisk AS $23.06 05/11/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897184247
Principal investigator 1 PFIZER INC. $23,318.55 05/06/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949750697
Principal investigator 1 PFIZER INC. $729.00 05/06/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949751151
Principal investigator 1 PFIZER INC. $370.00 05/05/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 949819035
Principal investigator 1 PFIZER INC. $827.66 05/03/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949750949
Principal investigator 1 Novo Nordisk AS $712.12 04/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896935111
Principal investigator 1 Novo Nordisk AS $1,421.45 04/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896957745
Principal investigator 1 Novo Nordisk AS $3,121.87 04/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896973867
Principal investigator 1 Novo Nordisk AS $250.00 04/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896980251
Principal investigator 1 Novo Nordisk AS $3,932.41 04/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009377
Principal investigator 1 Novo Nordisk AS $70.00 04/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897031835
Principal investigator 1 Novo Nordisk AS $4,488.76 04/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897236111
Principal investigator 1 Novo Nordisk AS $7,175.04 04/29/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897241585
Principal investigator 1 PFIZER INC. $1,228.50 04/29/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949818915
Principal investigator 1 Novo Nordisk AS $23.06 04/26/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896902910
Principal investigator 1 Janssen Pharmaceuticals, Inc $105,076.00 04/25/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219195
Principal investigator 1 PFIZER INC. $12,820.95 04/22/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949819785
Principal investigator 1 Novo Nordisk AS $23.06 04/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896905731
Principal investigator 1 Novo Nordisk AS $23.06 04/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897032415
Principal investigator 1 PFIZER INC. $1,241.49 04/20/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949820087
Principal investigator 1 PFIZER INC. $2,069.15 04/19/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949819033
Principal investigator 1 Novo Nordisk AS $23.06 04/18/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896949915
Principal investigator 1 Novo Nordisk AS $23.06 04/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897008958
Principal investigator 1 PFIZER INC. $526.50 04/14/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949820085
Principal investigator 1 Novo Nordisk AS $75.00 04/08/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896924997
Principal investigator 1 Novo Nordisk AS $23.06 04/05/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897176979
Principal investigator 1 Eli Lilly and Company $9,150.00 04/04/2022 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) No dispute reported 06/30/2026 917836085
Principal investigator 1 PFIZER INC. $10,079.10 04/01/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949819787
Principal investigator 1 PFIZER INC. $1,228.50 04/01/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949820083
Principal investigator 1 Novo Nordisk AS $2,581.04 03/31/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976242
Principal investigator 1 Novo Nordisk AS $70.00 03/31/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897107829
Principal investigator 1 PFIZER INC. $23,195.70 03/31/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949825899
Principal investigator 1 Novo Nordisk AS $23.06 03/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897175451
Principal investigator 1 Novo Nordisk AS $23.06 03/30/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897175455
Recipient PFIZER INC. $940.00 03/29/2022 Covered Recipient Physician PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 949783631
Principal investigator 1 PFIZER INC. $413.83 03/29/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949825897
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $8,265.77 03/28/2022 Non-covered Recipient Entity
PMG Research Inc
Phase II study of BI456906 in Patients with T2DM O No dispute reported 06/30/2026 949201809
Principal investigator 1 Janssen Pharmaceuticals, Inc $54,122.00 03/28/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219075
Principal investigator 1 Novo Nordisk AS $23.06 03/28/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897175447
Principal investigator 1 Novo Nordisk AS $8,743.17 03/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896916509
Principal investigator 1 Novo Nordisk AS $1,424.25 03/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896928221
Principal investigator 1 Novo Nordisk AS $1,148.32 03/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897073885
Principal investigator 1 Novo Nordisk AS $3,523.22 03/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897143643
Principal investigator 1 Novo Nordisk AS $4,225.36 03/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897175459
Principal investigator 1 PFIZER INC. $486.00 03/23/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949825411
Principal investigator 1 PFIZER INC. $2,896.81 03/22/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949825409
Principal investigator 1 Novo Nordisk AS $23.06 03/21/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897176987
Principal investigator 1 Janssen Pharmaceuticals, Inc $308,351.00 03/18/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219071
Principal investigator 1 Novo Nordisk AS $23.06 03/18/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897046764
Principal investigator 1 Novo Nordisk AS $23.06 03/18/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897118825
Recipient Novo Nordisk AS $54.00 03/17/2022 Covered Recipient Physician NN9536-4578 No dispute reported 06/30/2026 897263857
Principal investigator 1 PFIZER INC. $5,778.00 03/16/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949825895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,100.00 03/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938617957
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,300.00 03/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938617959
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,300.00 03/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938617961
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,400.00 03/14/2022 Non-covered Recipient Entity
ACCELLACARE US INC
A MASTER PROTOCOL ASSESSING THE SAFETY, TOLERABILITY, AND EFFICACY OF ANTI-SPIKE (S) SARS-COV-2 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF AMBULATORY PATIENTS WITH COVID-19 No dispute reported 06/30/2026 938617965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 03/10/2022 Non-covered Recipient Entity
PMG RESEARCH
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY ASSESSING THE EFFICACY AND SAFETY OF ANTI-SPIKE SARS-COV-2 MONOCLONAL ANTIBODIES IN PREVENTING SARS-COV-2 INFECTION IN HOUSEHOLD CONTACTS OF INDIVIDUALS INFECTED WITH SARS-COV-2 No dispute reported 06/30/2026 938617875
Principal investigator 1 Novo Nordisk AS $23.06 03/09/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897073941
Principal investigator 1 Novo Nordisk AS $23.06 03/09/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897083701
Principal investigator 1 Novo Nordisk AS $23.06 03/08/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897176119
Recipient Novo Nordisk AS $108.00 03/03/2022 Covered Recipient Physician NN9536-4578 No dispute reported 06/30/2026 897218431
Recipient Novo Nordisk AS $240.00 03/03/2022 Covered Recipient Physician EX9536-4773 No dispute reported 06/30/2026 897222379
Principal investigator 1 PFIZER INC. $911.25 03/03/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED TRIAL TO ASSESS THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF MENABCWY IN HEALTHY PARTICIPANTS 10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 949825457
Principal investigator 1 PFIZER INC. $45,582.75 03/03/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949825617
Principal investigator 1 Novo Nordisk AS $374.36 03/02/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897000111
Principal investigator 1 Novo Nordisk AS $23.06 03/01/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 896852161
Principal investigator 1 PFIZER INC. $10,208.15 03/01/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949825407
Principal investigator 1 Novo Nordisk AS $70.00 02/28/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897107825
Principal investigator 1 Novo Nordisk AS $23.06 02/28/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897107905
Principal investigator 1 Novo Nordisk AS $23.06 02/28/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897183137
Recipient PFIZER INC. $3,200.00 02/28/2022 Covered Recipient Physician COVID19 VACC CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 949783633
Principal investigator 1 Novo Nordisk AS $8,325.04 02/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896916459
Principal investigator 1 Novo Nordisk AS $16.50 02/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921753
Principal investigator 1 Novo Nordisk AS $16.50 02/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896928831
Principal investigator 1 Novo Nordisk AS $2,052.27 02/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897008963
Principal investigator 1 Novo Nordisk AS $5,265.27 02/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897107773
Principal investigator 1 Novo Nordisk AS $331.56 02/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897143639
Principal investigator 1 PFIZER INC. $56,542.05 02/25/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949830163
Principal investigator 1 Novo Nordisk AS $25.06 02/23/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897000115
Recipient Novo Nordisk AS $200.00 02/23/2022 Covered Recipient Physician NN9924-4635 No dispute reported 06/30/2026 897153359
Recipient Novo Nordisk AS $200.00 02/23/2022 Covered Recipient Physician NN9924-4473 No dispute reported 06/30/2026 897177339
Principal investigator 1 Boehringer Ingelheim International GmbH $24.60 02/18/2022 Non-covered Recipient Entity
Pmg Research Of Wilmington
BI 767551 EX14870 Ph II III SARS COV 2 Ambulato No dispute reported 06/30/2026 946885565
Principal investigator 1 Novo Nordisk AS $50.12 02/18/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897143651
Principal investigator 1 Novo Nordisk AS $25.06 02/18/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897176104
Principal investigator 1 Janssen Pharmaceuticals, Inc $255,551.00 02/16/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219067
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896859451
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896859453
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896859455
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896915069
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896916513
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896916525
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896917925
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896922599
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896922603
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896968085
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896968089
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896968093
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896968097
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896968243
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896979577
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896983519
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896983571
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896983575
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896984487
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896984491
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896997505
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896997513
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897004607
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897004611
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897004615
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897004619
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897042109
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897042113
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897074459
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897079923
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897079935
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897080657
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897123065
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897191073
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897194993
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897194997
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897195901
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897239033
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897241379
Principal investigator 1 Novo Nordisk AS $56.90 02/15/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 897242619
Principal investigator 1 Novo Nordisk AS $54.00 02/12/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896825
Principal investigator 1 Novo Nordisk AS $54.00 02/12/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896927493
Principal investigator 1 Novo Nordisk AS $54.00 02/12/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896930839
Principal investigator 1 Novo Nordisk AS $7,847.02 02/11/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918851
Principal investigator 1 Novo Nordisk AS $25.06 02/11/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897117877
Principal investigator 1 Novo Nordisk AS $8,451.30 02/09/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9536-4388 No dispute reported 06/30/2026 896922615
Principal investigator 1 Novo Nordisk AS $25.06 02/09/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897175443
Principal investigator 1 PFIZER INC. $79.00 02/08/2022 Non-covered Recipient Entity
ACCELLACARE
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 949810465
Principal investigator 1 Novo Nordisk AS $963.00 02/07/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 897021567
Principal investigator 1 Novo Nordisk AS $2,843.18 02/07/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897046767
Principal investigator 1 Novo Nordisk AS $1,123.07 02/07/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897075391
Principal investigator 1 Novo Nordisk AS $2,080.12 02/07/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897236233
Principal investigator 1 Novo Nordisk AS $120.00 02/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896862599
Principal investigator 1 Novo Nordisk AS $120.00 02/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896928169
Principal investigator 1 Novo Nordisk AS $120.00 02/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896928173
Principal investigator 1 Novo Nordisk AS $120.00 02/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896935103
Principal investigator 1 Novo Nordisk AS $120.00 02/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896935107
Principal investigator 1 Novo Nordisk AS $120.00 02/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896980247
Principal investigator 1 Novo Nordisk AS $120.00 02/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 896987981
Principal investigator 1 Novo Nordisk AS $120.00 02/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 897006199
Principal investigator 1 Novo Nordisk AS $120.00 02/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 897016363
Principal investigator 1 Novo Nordisk AS $120.00 02/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN1436-4481 No dispute reported 06/30/2026 897021571
Principal investigator 1 PFIZER INC. $24,225.75 02/04/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949827663
Principal investigator 1 PFIZER INC. $109,975.05 02/04/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949830169
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $146,453.76 02/03/2022 Non-covered Recipient Entity
PMG Research Inc
Ph IIb dose finding vs placebo in patients with Ob No dispute reported 06/30/2026 949200067
Principal investigator 1 Novo Nordisk AS $25.06 02/02/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897143645
Principal investigator 1 PFIZER INC. $2,482.98 02/01/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949827333
Principal investigator 1 Novo Nordisk AS $70.00 01/31/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897186683
Principal investigator 1 Novo Nordisk AS $25.06 01/25/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 896905727
Principal investigator 1 Janssen Pharmaceuticals, Inc $64,146.00 01/21/2022 Non-covered Recipient Entity
Accellacare Us Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 885219063
Principal investigator 1 PFIZER INC. $430.65 01/21/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949828401
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854009
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854071
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854073
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854075
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854077
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854079
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854087
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854089
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854091
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896860813
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896860821
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896860825
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896860849
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896872233
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896872241
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896872245
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896872249
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896872253
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896872257
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896872261
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896888693
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896888721
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896888725
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896888733
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896888739
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896888745
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896888753
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896888803
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896782
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896787
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896789
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896793
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896799
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896802
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896810
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896817
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896821
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896867
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918855
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918859
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918863
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918871
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918885
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918889
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918891
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918895
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921633
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921757
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921765
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921769
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921773
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921777
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921781
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921785
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896921797
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896924965
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896924977
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896924981
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896924985
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896924989
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896925069
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896925073
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896925077
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896925101
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896927477
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896927485
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896927489
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896928791
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896928835
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896928839
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896928843
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896928847
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896928861
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896930831
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896930835
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896931489
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976137
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976245
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976249
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976253
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976257
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976261
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976265
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976279
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976283
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896976287
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896983649
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896983713
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896983867
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896983871
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896983875
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896983879
Principal investigator 1 Novo Nordisk AS $12.99 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896983891
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896985069
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896985073
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896985077
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896985085
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001185
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001190
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001195
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001222
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001225
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001230
Principal investigator 1 Novo Nordisk AS $12.99 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001233
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001239
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009217
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009385
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009389
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009393
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009397
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009401
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009405
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009417
Principal investigator 1 Novo Nordisk AS $2.85 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009421
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009425
Principal investigator 1 Novo Nordisk AS $15.45 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009637
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009641
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897031145
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897104683
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897104687
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897105443
Principal investigator 1 Novo Nordisk AS $5.69 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897159709
Principal investigator 1 Novo Nordisk AS $3.25 01/20/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897161985
Principal investigator 1 Novo Nordisk AS $25.06 01/19/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897175963
Principal investigator 1 PFIZER INC. $3,310.64 01/19/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949829217
Principal investigator 1 Novo Nordisk AS $22.86 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854081
Principal investigator 1 Novo Nordisk AS $6.32 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896854083
Principal investigator 1 Novo Nordisk AS $6.32 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896860815
Principal investigator 1 Novo Nordisk AS $6.32 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896860817
Principal investigator 1 Novo Nordisk AS $6.32 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896896753
Principal investigator 1 Novo Nordisk AS $6.32 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 896918867
Principal investigator 1 Novo Nordisk AS $6.32 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001198
Principal investigator 1 Novo Nordisk AS $6.32 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001201
Principal investigator 1 Novo Nordisk AS $6.32 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897001205
Principal investigator 1 Novo Nordisk AS $6.32 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897009671
Principal investigator 1 Novo Nordisk AS $6.32 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897104565
Principal investigator 1 Novo Nordisk AS $6.32 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9536-4578 No dispute reported 06/30/2026 897105447
Principal investigator 1 Novo Nordisk AS $25.06 01/17/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897118125
Principal investigator 1 Novo Nordisk AS $25.06 01/14/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897175439
Principal investigator 1 Novo Nordisk AS $25.06 01/13/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9924-4635 No dispute reported 06/30/2026 897235907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 01/13/2022 Non-covered Recipient Entity
PMG RESEARCH
A PHASE 2 STUDY TO ASSESS THE VIROLOGIC EFFICACY OF REGN10933+REGN10987 ACROSS DIFFERENT DOSE REGIMENS IN OUTPATIENTS WITH SARS-COV-2 INFECTION No dispute reported 06/30/2026 938613615
Recipient Novo Nordisk AS $270.00 01/12/2022 Covered Recipient Physician NN9924-4473 No dispute reported 06/30/2026 897177333
Recipient Novo Nordisk AS $270.00 01/12/2022 Covered Recipient Physician NN9924-4473 No dispute reported 06/30/2026 897205173
Recipient Novo Nordisk AS $200.00 01/12/2022 Covered Recipient Physician NN9924-4473 No dispute reported 06/30/2026 897263841
Recipient Novo Nordisk AS $200.00 01/12/2022 Covered Recipient Physician NN9924-4473 No dispute reported 06/30/2026 897266005
Principal investigator 1 PFIZER INC. $5,800.00 01/12/2022 Non-covered Recipient Entity
PMG Research Inc
A PHASE 123 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND DOSEFINDING STUDY TO EVALUATE THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF SARSCOV2 RNA VACCINE CANDIDATES AGAINST COVID19 IN HEALTHY ADULTS No dispute reported 06/30/2026 949829149
Principal investigator 1 PFIZER INC. $1,364.58 01/12/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF 3 LOTS OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN HEALTHY ADULTS No dispute reported 06/30/2026 949829643
Principal investigator 1 PFIZER INC. $4,990.95 01/08/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSES OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2 No dispute reported 06/30/2026 949828403
Principal investigator 1 PFIZER INC. $41,237.10 01/08/2022 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 STUDY TO EVALUATE THE EFFICACY IMMUNOGENICITY AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN ADULTS No dispute reported 06/30/2026 949829875
Principal investigator 1 Novo Nordisk AS $25.06 01/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897073209
Principal investigator 1 Novo Nordisk AS $25.06 01/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897083705
Principal investigator 1 Novo Nordisk AS $25.06 01/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
EX9924-4473 No dispute reported 06/30/2026 897117895
Principal investigator 1 Novo Nordisk AS $25.06 01/04/2022 Non-covered Recipient Entity
PMG RESEARCH, INC
NN9535-4321 No dispute reported 06/30/2026 897122335